Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open-label, Positive Drug Parallel Controlled Clinical Trial of Kesuting Syrup in the Treatment of COVID-19 (Light)

NCT05366231 is registered in ClinicalTrials.gov with Guizhou Bailing Group Pharmaceutical Co Ltd as lead sponsor.

NCT NCT05366231
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05366231 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open-label, Positive Drug Parallel Controlled Clinical Trial of Kesuting Syrup in the Treatment of COVID-19 (Light)
Lead sponsor
Guizhou Bailing Group Pharmaceutical Co Ltd
Phase
Phase 4
Overall status
Completed
Start date
May 8, 2022
Completion date
September 15, 2022
Enrollment
200 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cough, covid-19 pneumonia